bioRxivImmunology
Canonical and cross-reactive binding of NK cell inhibitory receptors to HLA-C allotypes is dictated by peptides bound to HLA-C
M. J. W. Sim, S. A. Malaker, A. Khan, J. M. Stowell, J. Shabanowitz, M. E. Peterson, S. Rajagopalan, D. F. Hunt, D. M. Altmann, E. O. Long, R. J. Boyton
Abstract
BackgroundHuman natural killer (NK) cell activity is regulated by a family of killer-cell Ig-like receptors (KIR) that bind human leucocyte antigen (HLA) class I. Combinations of KIR and HLA genotypes are associated with disease, including susceptibility to viral infection and disorders of pregnancy. KIR2DL1 binds HLA-C alleles of group C2 (Lys80) and KIR2DL2 and KIR2DL3 bind HLA-C alleles of group C1 (Asn80). However, this model does not capture allelic diversity in HLA-C or the impact of HLA-bound peptides. The goal of this study was to determine the extent to which the endogenous HLA-C peptide repertoire can influence the specific binding of inhibitory KIR to HLA-C allotypes.\n\nResultsThe impact of HLA-C bound peptide on inhibitory KIR binding was investigated taking advantage of the fact that HLA-C*05:01 (HLA-C group 2, C2) and HLA-C*08:02 (HLA-C group 1, C1) have identical sequences apart from the key KIR specificity determining epitope at residues 77 and 80. Endogenous peptides were eluted from HLA-C*05:01 and used to test the peptide dependence of KIR2DL1 and KIR2DL2/3 binding to HLA-C*05:01 and HLA-C*08:02 and subsequent impact on NK cell function. Specific binding of KIR2DL1 to the C2 allotype occurred with the majority of peptides tested. In contrast, KIR2DL2/3 binding to the C1 allotype occurred with only a subset of peptides. Cross-reactive binding of KIR2DL2/3 with the C2 allotype was restricted to even fewer peptides. Unexpectedly, two peptides promoted binding of the C2 allotype-specific KIR2DL1 to the C1 allotype. We showed that presentation of endogenous peptides, or predicted HIV Gag peptides, by HLA-C can promote KIR cross-reactive binding.\n\nConclusionsKIR2DL2/3 binding to C1 is more peptide selective than that of KIR2DL1 binding to C2, which provides an explanation for why KIR2DL3-C1 interactions appear weaker than KIR2DL1-C2. In addition, cross-reactive binding of KIR is characterized by even higher peptide selectivity. We demonstrate a hierarchy of functional peptide selectivity of KIR-HLA-C interactions with relevance to NK cell biology and human disease associations. This selective peptide sequence-driven binding of KIR provides a potential mechanism for pathogen as well as self-peptide to modulate NK cell activation through altering levels of inhibition.
- organism: human
- assay: proteomics
- research focus: cell type annotation
- research focus: cell signaling & trafficking
- research focus: host-pathogen & immune response
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Innate receptors with high specificity for HLA class I-peptide complexes
M. J. W. Sim, P. Brennan, … E. O. Long·bioRxiv·Feb 6, 2023
- Using peptide-exchange systems to interrogate peptide-specific KIR binding to HLA Class -I
Tanusya Murali Murali, Beining Li, … Malcolm J. W. Sim·Discovery ImmunologyPeer-reviewed·Jan 1, 2026
- An unbiased characterization of the HLA-E and CD94/NKG2x peptide repertoire reveals peptide ligands that skew NK cell activation
B. D. Huisman, N. Guan, … M. E. Birnbaum·bioRxiv·Aug 3, 2022
- HLA-C-restricted presentation of a conserved bacterial epitope to an innate NK cell receptor
M. J. W. Sim, S. Rajagopalan, … E. O. Long·bioRxiv·Feb 15, 2019
- Allosteric disulfide control of ligand binding and endocytosis of KIR2DL4, the natural killer cell receptor for HLA-G
Sumati Rajagopalan, Joyce Chiu, … Eric O. Long·eLifePeer-reviewed·Oct 13, 2026
- Genetically Determined Strength of Natural Killer Cells is Enhanced by Adaptive HLA class I Admixture in East Asians
Z. Deng, J. Zhen, … P. J. Norman·bioRxiv·Jul 29, 2020